- |||||||||| RB-340 / Refuge Biotech, UT MD Anderson Cancer Center
Journal, CAR T-Cell Therapy, PD(L)-1 Biomarker, IO biomarker: Contextual reprogramming of CAR-T cells for treatment of HER2 cancers. (Pubmed Central) - Dec 16, 2021
As the first application of CRISPRi toward a clinically relevant product, RB-340-1 with the conditional, non-gene editing and reversible suppression promotes CAR-T cells resilience to checkpoint inhibition, and their persistence and effectiveness against HER2-expressing cancer xenografts.
|
